Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers find treatments that preserve ovarian function in young women with cancer

04.06.2003


Two studies by researchers at The University of Texas M. D. Anderson Cancer Center have identified treatments that appear helpful in preserving ovarian function in pre-menopausal women with cancer.



The unrelated analyses, to be presented at different times during the annual meeting of the American Society of Clinical Oncology, are the first to focus on the desire of many younger patients with breast as well as other cancers to maintain fertility, as well as to protect their bones, hearts, and sexual functioning.

One study, led by Nuhad K. Ibrahim, M.D., associate professor of breast medical oncology, found that breast cancer patients who used a paclitaxel-based chemotherapy regimen may preserve ovarian function compared with patients treated just with standard chemotherapy.


The other analysis, conducted by Naoto Ueno, M.D., Ph.D., assistant professor of blood and marrow transplantation, concluded that patients treated with "mini" allogeneic transplants for a variety of cancers also had a significantly greater chance of protecting their ovaries compared to patients given high dose chemo- or chemoradiation therapy with transplant.

1. Substituting Taxol in Chemotherapy Regimen Preserves Ovarian Fun

A follow-up study of hundreds of pre-menopausal patients treated for early stage breast cancer at M. D. Anderson found that partial use of paclitaxel (TaxolTM) with standard adjuvant chemotherapy significantly improved a younger woman’s chance that she could regain her ovarian function.

The standard chemotherapy regimen, known as FAC, includes adriamycin and cyclophosphamide with or without 5-fluorouracil.

The analysis, culled from a larger study of 580 breast cancer patients, compared ovarian function and outcomes in younger women who received eight rounds of FAC versus patients who received four rounds of FAC followed by four rounds of paclitaxel.

In a group of 29 women who received just FAC treatment, 20 women (69 percent) had permanent loss of ovarian function, six women (21 percent) had a transient loss of ovarian function, and three patients (10 percent) never lost it. But in 59 women who had been treated with the "four plus four" regimen, 28 patients (47 percent) lost use of their ovaries, while 26 patients (44 percent) had a transient lost, and 5 patients (8 percent) never lost ovarian function.

Four women who used paclitaxel subsequently became pregnant, compared to just one patient treated only with FAC, reports Ibrahim.

The results are important because, at M. D. Anderson, up to half of all breast cancer patients treated are younger than 50 years old, says Ibrahim.

"This is not just an issue of fertility, but also of maintaining other healthy issues that are usually associated with premature menopause, such as osteoporosis, an increase of lipids in the blood stream and associated heart diseases, as well as sexual and cognitive health.

"If the clinical outcome between the patients treated with FAC alone or with FAC and paclitaxel is equivalent, then there is no reason not to offer the paclitaxel-based regimen for the patients who desire to preserve fertility, or to delay premature menopause," Ibrahim says.

2. Mini Transplants, Used to Treat Many Cancers, Can Save Ovaries

The second study found that in treating a variety of cancers with donor stem cell transplantation, use of low-dose chemotherapy was much better at preserving ovarian function than was high-dose chemotherapy.

The retrospective analysis included 3,945 patients who had received stem cell transplants between 1987 and 2001, and looked at the outcome of women younger than age 50 who were being treated for any malignancy other than breast or ovarian cancer.

Results show that of the 77 patients who received high-dose chemotherapy followed by stem cell transplantation, 79 percent lost ovarian function as seen in loss of their menstrual cycle. In contrast, 16 patients treated with low-dose chemotherapy and stem cell rescue (a so-called "mini-transplantation"), only 37.5 percent lost use of their ovaries.

"It’s very exciting to find a transplantation regimen that can protect a woman’s ovaries because this can truly be of benefit to our patients to improve long-term quality of life," says Ueno. "Of course, this can only be proven with a prospective trial, but it makes sense that a weaker regimen would be less toxic."

Mini transplants are most often used to treat leukemia, lymphoma and certain solid tumors.


Contact: Stephanie Dedeaux or Laura Sussman, (713) 792-0655


Laura Sussman | EurekAlert!

More articles from Health and Medicine:

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Cloud Formation: How Feldspar Acts as Ice Nucleus

09.12.2016 | Life Sciences

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>